

## PRESS RELEASE

## Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence

**Bengaluru, Karnataka, India, December 11, 2024**

**Biocon Biologics Limited**, a subsidiary of **Biocon Limited (BSE: 532523, NSE: BIOCON)**, announced today that it has once again been recognized as an **Asia IP Elite for 2024** by **IAM (Intellectual Asset Management)**, the world's leading **Intellectual Property (IP) publication**. This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.

This prestigious accolade is awarded to a select group of Asia-based organisations that have demonstrated exceptional IP value creation and are considered leaders in the region.

In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on the prestigious ASIA IP ELITE list for its robust IP management and consistent IP value creation.

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the **Asia IP Elite 2024** list.

**Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said:** *“We are humbled to be recognized for the eighth consecutive year as an Asia IP Elite company by IAM, a testament to our commitment to innovation, intellectual property excellence, and patient-centric solutions. This accolade reinforces Biocon Biologics’ position as a leading global biosimilars company and underscores the critical role of our robust IP strategy in enabling affordable access to high-quality biosimilar therapies worldwide. Our dedicated team continues to place IP at the core of our business, driving value creation and advancing healthcare solutions for millions of patients globally.”*

Biocon Biologics is leveraging its robust in-house IP strategy and capabilities to enable early entry of biosimilar products to meet patients’ needs for affordable therapy in global markets.

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite. This is a remarkable achievement and well-deserved recognition for the company and its entire IP team.

Each member of the Asia IP Elite showcases excellence in IP value creation and meets the following criteria:

- Placing IP strategy at the centre of its business.
- Obtaining demonstrable, significant and ongoing value from intellectual property as a direct result of the strategies it employs.
- Possessing a senior management that understands the operational and strategic importance of intellectual property.
- Constantly reappraising and improving its IP strategy in order to take advantage of market developments.

This year, 93 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the **Asia IP Elite 2024** list.

### About IAM

Intellectual Asset Management (IAM) is a bimonthly magazine published by Globe White Page, which provides worldwide insight and expertise on managing intellectual property as a key business asset. Its suite of tools, intelligence, legal know-how and data empowers companies to mitigate risks, optimize operations, spot new commercial opportunities and maximize the value of patent, trade secret and other IP assets. [www.iam-media.com](http://www.iam-media.com)

### About Biocon Biologics Ltd.

**Biocon Biologics Limited**, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: [www.bioconbiologics.com](http://www.bioconbiologics.com); Follow us on X (*formerly Twitter*): @BioconBiologics and LinkedIn: [Biocon Biologics](#) for company updates.

**Biocon Limited**, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: [www.biocon.com](http://www.biocon.com); Follow-us on X (*formerly Twitter*): @bioconlimited and LinkedIn: [Biocon](#) for company updates.

**FOR MORE INFORMATION**

**MEDIA****Seema Ahuja**

Global Head of Corporate Brand  
& Head of Communications – Emerging Markets  
Biocon Biologics

M: +91 99723 17792

E: [seema.ahuja@biocon.com](mailto:seema.ahuja@biocon.com)

**INVESTORS****Saurabh Paliwal**

Head - Investor Relations

Biocon

M: +91 95383 80801

E: [saurabh.paliwal@biocon.com](mailto:saurabh.paliwal@biocon.com)